AC Immune SA annual r&d spending
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
AC Immune SA R&D Spending Growth & History (ACIU)
AC Immune SA's r&d spending was CHF56.4M for fiscal 2025.
View full AC Immune SA company overviewAC Immune SA annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | CHF56.4M | −CHF6.1M | −9.80% |
| 2024 | 2024-12-31 | CHF62.6M | CHF8.0M | +14.58% |
| 2023 | 2023-12-31 | CHF54.6M | −CHF5.7M | −9.50% |
| 2022 | 2022-12-31 | CHF60.3M | −CHF1.9M | −3.12% |
| 2021 | 2021-12-31 | CHF62.3M | CHF2.8M | +4.70% |
| 2020 | 2020-12-31 | CHF59.5M | CHF9.1M | +17.95% |
| 2019 | 2019-12-31 | CHF50.4M | CHF6.2M | +13.90% |
| 2018 | 2018-12-31 | CHF44.3M | CHF11.6M | +35.56% |
| 2017 | 2017-12-31 | CHF32.7M | CHF6.9M | +26.73% |
| 2016 | 2016-12-31 | CHF25.8M | CHF8.7M | +51.18% |
| 2015 | 2015-12-31 | CHF17.0M | — | — |
AC Immune SA quarterly r&d spending
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q3.21
Q2.22
Q3.22
Q2.23
Q2.24
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | CHF10.5M | −CHF6.3M | −37.74% |
| Q1 2026 | 2026-03-31 | CHF11.7M | — | — |
| Q4 2025 | 2025-12-31 | CHF10.6M | — | — |
| Q3 2025 | 2025-09-30 | CHF13.1M | — | — |
| Q2 2025 | 2025-06-30 | CHF16.8M | −CHF312,000 | −1.82% |
| Q2 2024 | 2024-06-30 | CHF17.1M | CHF3.5M | +25.26% |
| Q2 2023 | 2023-06-30 | CHF13.7M | −CHF2.0M | −12.81% |
| Q3 2022 | 2022-09-30 | CHF14.4M | −CHF733,000 | −4.85% |
| Q2 2022 | 2022-06-30 | CHF15.7M | — | — |
| Q3 2021 | 2021-09-30 | CHF15.1M | — | — |
| Q4 2018 | 2018-12-31 | CHF12.1M | CHF2.0M | +19.19% |
| Q3 2018 | 2018-09-30 | CHF11.5M | CHF3.4M | +40.89% |
| Q2 2018 | 2018-06-30 | CHF10.5M | CHF3.7M | +54.04% |
| Q1 2018 | 2018-03-31 | CHF10.1M | CHF2.6M | +35.08% |
| Q4 2017 | 2017-12-31 | CHF10.2M | — | — |
| Q3 2017 | 2017-09-30 | CHF8.2M | — | — |
| Q2 2017 | 2017-06-30 | CHF6.8M | — | — |
| Q1 2017 | 2017-03-31 | CHF7.5M | — | — |
AC Immune SA r&d spending trends
Over the last five fiscal years, AC Immune SA's r&d spending decreased from CHF59.5M to CHF56.4M, a change of −CHF3.1M. The latest reported quarter, Q2 2026, shows CHF10.5M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review AC Immune SA source filings ↗